Aimbire F, Lopes-Martins R A B, Albertini R, Pacheco M T T, Castro-Faria-Neto H C, Martins P S L L, Bjordal J M
Laboratory of Animal Experimentation, Research and Development Institute (IP&D), Vale do Paraíba University (UNIVAP), São José dos Campos, Brazil.
Photomed Laser Surg. 2007 Apr;25(2):112-7. doi: 10.1089/pho.2006.1041.
The aim of this study was to investigate if low-level laser therapy (LLLT) can modulate formation of hemorrhagic lesions induced by immune complex.
There is a lack of information on LLLT effects in hemorrhagic injuries of high perfusion organs, and the relative efficacy of LLLT compared to anti-inflammatory drugs.
A controlled animal study was undertaken with 49 male Wistar rats randomly divided into seven groups. Bovine serum albumin (BSA) i.v. was injected through the trachea to induce an immune complex lung injury. The study compared the effect of irradiation by a 650-nm Ga-Al-As laser with LLLT doses of 2.6 Joules/cm(2) to celecoxib, dexamethasone, and control groups for hemorrhagic index (HI) and myeloperoxide activity (MPO) at 24 h after injury.
The HI for the control group was 4.0 (95% CI, 3.7-4.3). Celecoxib, LLLT, and dexamethasone all induced significantly (p < 0.01) lower HI than control animals at 2.5 (95% CI, 1.9-3.1), 1.8 (95% CI, 1.2-2.4), and 1.5 (95% CI, 0.9-2.1), respectively, for all comparisons to control. Dexamethasone, but not celecoxib, induced a slightly, but significantly lower HI than LLLT (p = 0.04). MPO activity was significantly decreased in groups receiving celecoxib at 0.87 (95% CI, 0.63-1.11), dexamethasone at 0.50 (95% CI, 0.24-0.76), and LLLT at 0.7 (95% CI, 0.44-0.96) when compared to the control group, at 1.6 (95% CI, 1.34-1.96; p < 0.01), but there were no significant differences between any of the active treatments.
LLLT at a dose of 2.6 Joules/cm(2) induces a reduction of HI levels and MPO activity in hemorrhagic injury that is not significantly different from celecoxib. Dexamethasone is slightly more effective than LLLT in reducing HI, but not MPO activity.
本研究旨在调查低强度激光疗法(LLLT)是否能调节免疫复合物诱导的出血性病变的形成。
关于LLLT在高灌注器官出血性损伤中的作用以及与抗炎药物相比LLLT的相对疗效,目前缺乏相关信息。
进行了一项对照动物研究,将49只雄性Wistar大鼠随机分为七组。通过气管静脉注射牛血清白蛋白(BSA)以诱导免疫复合物性肺损伤。该研究比较了650纳米镓铝砷激光以2.6焦耳/平方厘米的LLLT剂量照射与塞来昔布、地塞米松及对照组在损伤后24小时的出血指数(HI)和髓过氧化物活性(MPO)。
对照组的HI为4.0(95%可信区间,3.7 - 4.3)。与对照组相比,塞来昔布、LLLT和地塞米松在所有比较中均使HI显著降低(p < 0.01),分别为2.5(95%可信区间,1.9 - 3.1)、1.8(95%可信区间,1.2 - 2.4)和1.5(95%可信区间,0.9 - 2.1)。地塞米松诱导的HI略低于LLLT,但差异有统计学意义(p = 0.04),而塞来昔布则无此差异。与对照组相比,接受塞来昔布组的MPO活性显著降低至0.87(95%可信区间,0.63 - 1.11),地塞米松组为0.50(95%可信区间,0.24 - 0.76),LLLT组为0.7(95%可信区间,0.44 - 0.96),对照组为1.6(95%可信区间,1.34 - 1.96;p < 0.01),但各活性治疗组之间无显著差异。
2.6焦耳/平方厘米剂量的LLLT可使出血性损伤中的HI水平和MPO活性降低,与塞来昔布相比无显著差异。地塞米松在降低HI方面比LLLT略有效,但在降低MPO活性方面则不然。